logo

Zai Lab Limited (ZLAB)



Trade ZLAB now with
  Date
  Headline
3/19/2020 7:34:10 AM Zai Lab FY Loss Per Share $2.64 Vs Loss $3.03 Last Year
2/10/2020 7:39:59 AM Zai Lab Announces China NMPA Accepts NDA For Omadacycline
1/14/2020 7:33:34 AM Zai Lab Appoints Lonnie Moulder To Its Board
1/9/2020 7:37:59 AM Zai Lab, Novocure Say First Patient Enrolled In Phase 2 Pilot Trial Of Tumor Treating Fields Together With Chemotherapy
1/9/2020 7:34:16 AM Zai Lab, Novocure : First Patient Enrolled In Phase 2 Pilot Trial Of Tumor Treating Fields Together With Chemotherapy
12/27/2019 7:54:47 AM Zai Lab Reports NMPA Approval Of ZEJULA In China As Maintenance Therapy For Patients With Recurrent Ovarian Cancer
12/16/2019 7:36:27 AM Zai Lab Appoints Timothy Yap To Its Scientific Advisory Board
10/25/2019 8:36:49 AM Zai Lab Partner, MacroGenics Begin Phase 2/3 MAHOGANY Study Of Margetuximab In Gastric Junction Cancer
7/2/2019 7:35:18 AM Incyte And Zai Lab Announce Collaboration And License Agreement For INCMGA0012 In Greater China
6/11/2019 7:09:14 AM Deciphera Pharma And Zai Lab Announce Exclusive License Agreement For Ripretinib In Greater China
2/1/2019 7:30:53 AM Zai Lab Appoints Immuno-Oncology Pioneer, Lieping Chen, To Scientific Advisory Board
1/28/2019 7:33:58 AM Zai Lab Says CFDA Grants Priority Review Status To NDA For ZEJULA
1/9/2019 7:32:04 AM Zai Lab Completes Patient Enrollment Of Its Pivotal Trial Of Niraparib
12/28/2018 7:30:58 AM Zai Lab Announces Launch Of Optune In Hong Kong
12/12/2018 7:35:26 AM Zai Lab Announces Acceptance Of NDA Submission Of ZEJULA In Mainland China By NMPA
10/22/2018 7:35:16 AM Zai Lab Announces Approval Of ZEJULA For Patients With Relapsed Ovarian Cancer In Hong Kong
10/1/2018 8:12:58 AM Five Prime Therapeutics, Zai Lab Dose First Patient In Phase 3, Global Registrational Trial Of Bemarituzumab